Going Mad withSmads
- 7 October 1999
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 341 (15) , 1144-1146
- https://doi.org/10.1056/nejm199910073411510
Abstract
In the past year, several studies of mice with genetically manipulated Smad genes have caught the attention of cancer researchers. Smad is a family of at least nine genes, each bearing an identifying number (e.g., Smad1, Smad2, and Smad9), and each encoding a protein involved in mediating cellular responses to transforming growth factor β (TGF-β) and related polypeptides. The prototype for this family of ligands was named “transforming growth factor” because it was initially identified as a serum component that stimulated neoplastic-like behavior in fibroblasts. Now we know that it has important roles in the life and death of . . .Keywords
This publication has 5 references indexed in Scilit:
- Targeted Disruption of Smad3 Reveals an Essential Role in Transforming Growth Factor β-Mediated Signal TransductionMolecular and Cellular Biology, 1999
- Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-betaThe EMBO Journal, 1999
- Smad3 Mutant Mice Develop Metastatic Colorectal CancerCell, 1998
- TGF-β SIGNAL TRANSDUCTIONAnnual Review of Biochemistry, 1998
- Intestinal Tumorigenesis in Compound Mutant Mice of both Dpc4(Smad4) and Apc GenesCell, 1998